AKT1 and prostate carcinoma: Thus we demonstrate that cell growth and cell proliferative responses observed in prostate cancer cells treated with α2M* (6–10,12,41,46 and Figure 1) require cell surface expression of GRP78 and PI 3-kinase/Akt/mTOR signaling.